3 completed. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 2 |
Follow Relapse Leukemia: new trials by email Literature Review of Relapse Leukemia trials Research Report on Relapse Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm CD123 targeted CAR-NK cells - Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 / Phase 2 | Completed | Chongqing Precision Biotech Co., Ltd | 5 | 2024-03-28 | 2026-08-05 |
| Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia chimeric antigen receptor T cell - Acute Myeloid Leukemia, Relapse Leukemia | Phase 1 / Phase 2 | Completed | Beijing Boren Hospital | 5 | 2021-04-08 | 2024-06-21 |
| Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML LP-108, LP-108 and azacitidine - AML/MDS, CMML | Phase 1 | Completed | Newave Pharmaceutical Inc | 32 | 2020-07-06 | 2026-01-23 |
Leukemia, Myeloid, Acute (3) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Leukemia (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Leukemia, Myeloid (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Leukemia (2) · Disease Attributes (1) · Hematologic Neoplasms (1) · Histiocytic Disorders, Malignant (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoproliferative Disorders (1)
Azacitidine (1)
Beijing Boren Hospital (1) · Chongqing Precision Biotech Co., Ltd (1) · Newave Pharmaceutical Inc (1)
China (2) · Spain (1) · United States (1)
Jia Wei, M.D (1) · Jing Pan, MD/PhD (1)